Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
SELECTA BIOSCIENCES INC (SELB)
|
Add to portfolio |
|
|
|
| Price: |
$3.90
| | Metrics |
| OS: |
153.4
|
M
| |
|
|
| Market cap: |
$598
|
M
| |
|
|
|
Net cash:
|
$88
|
M
| |
$0.57
|
per share
|
|
EV:
|
$510
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$28.2
|
M
| |
18.1
|
x EV/EBITDA
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 110.8 | 85.1 | 16.6 | 6.7 | 0.9 | 0.2 | 8.1 | 6.0 |
| Revenue growth | 30.2% | 412.6% | 148.6% | 639.4% | 336.2% | -97.4% | 34.5% | 97.7% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 110.8 | 85.1 | 16.6 | 6.7 | 0.9 | 0.2 | 8.1 | 6.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 72.4 | 68.7 | 54.5 | 42.7 | 47.7 | 45.2 | 29.7 | 23.0 |
| General and administrative | 23.9 | 20.9 | 18.9 | 16.4 | 18.2 | 18.8 | 13.1 | 8.3 |
| EBIT | 14.5 | -4.6 | -56.8 | -52.5 | -65.0 | -63.8 | -34.7 | -25.3 |
| EBIT margin | 13.1% | -5.4% | -342.4% | -785.6% | -7200.7% | -30813.5% | -428.9% | -421.0% |
| Pre-tax income | 34.8 | -9.7 | -68.9 | -55.4 | -65.3 | -65.3 | -36.2 | -25.2 |
| Income taxes | -0.6 | 16.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | 35.4 | -25.7 | -68.9 | -55.4 | -65.3 | -65.3 | -40.8 | -32.5 |
| Net margin | 31.9% | -30.2% | -415.0% | -829.0% | -7235.4% | -31556.0% | -504.5% | -540.8% |
| |
| Diluted EPS | $0.24 | ($0.22) | ($0.68) | ($1.22) | ($2.92) | ($3.20) | ($3.89) | ($15.12) |
| Shares outstanding (diluted) | 145.9 | 114.3 | 101.2 | 45.5 | 22.4 | 20.4 | 10.5 | 2.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|